The long-held biological dogma that gene-editing machinery must rely on fragile RNA strands to find its target has finally been dismantled by a pioneering shift toward DNA-guided navigation. For years, the scientific community accepted the inherent instability of RNA as a necessary trade-off for
Modern medical science is increasingly looking toward the most aggressive cancer treatments as a potential solution for the chronic, debilitating nature of systemic autoimmune diseases. A pioneering clinical breakthrough at the University Hospital Erlangen in Germany has demonstrated that Chimeric
The clinical landscape for advanced medicine reached a definitive turning point on May 8, 2026, when Guy’s and St Thomas’ NHS Foundation Trust successfully completed its first inspection under the 3rd Edition Immune Effector Cells Standards. This milestone represents a significant departure from
The recent validation of Rimcato-joo by the Ministry of Food and Drug Safety represents a seismic shift in South Korea’s medical landscape, proving that domestic firms can move beyond manufacturing biosimilars into the high-stakes arena of personalized genetic medicine. For years, the local biotech
Ivan Kairatov is a distinguished expert in the biopharmaceutical sector, recognized for his deep specialization in research and development and the integration of innovative technologies in cancer care. His work frequently bridges the gap between complex bioengineering and clinical application,
The ALARIC clinical trial represents a monumental leap forward in the treatment of light chain amyloidosis, marking the first time that European researchers have utilized Chimeric Antigen Receptor (CAR) T-cell therapy for this specific patient population. Led by a collaborative team from University
